Role of microparticles in atherothrombosis
Fecha: noviembre 2016
Rosa Suades Soler
Monografías
Sumario
- ACKNOWLEDGMENTS
- PREFACE
- SUMMARY
- RESUMEN
- 1.1. CARDIOVASCULAR DISEASE
- 1.2. CELL-DERIVED MICROPARTICLES
- 1.3. CONCLUDING REMARKS AND UNRESOLVED ISSUES
- REFERENCES
- 3.1. STUDY DESIGN
- 3.2. CLINICAL STUDY POPULATIONS
- 3.3. BLOOD SAMPLING AND CLINICAL DETERMINATIONS
- 3.4. MICROPARTICLE ISOLATION
- 3.5. FLOW CYTOMETRY OF CIRCULATING MICROPARTICLES
- 3.6. FUNCTIONAL STUDIES
- 3.7. DIFFERENTIAL PROTEOMICS STUDIES
- 3.8. MICRORNA ANALYSIS
- 3.9. VALIDATION TECHNIQUES
- 3.10. IN SILICO BIOINFORMATIC ANALYSES
- 3.11. STATISTICAL ANALYSES
- REFERENCES
- Article 1. Circulating and platelet-derived microparticles In human blood enhance thrombosis on atherosclerotic plaques
- Article 2. Lipid-lowering therapy with statins reduces microparticles shedding from endothelium, platelets and inflammatory cells
- Article 3. Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in FH patients
- Article 4. High levels of TSP1+/CD142+ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis
- Article 5. Growing thrombi release increased levels of CD235a+ microparticles and decreased levels of activated platelet-derived microparticles. Validation in ST-elevation myocardial infarction patients
- Article 6. Circulating microparticle signature in coronary and peripheral blood of ST elevation myocardial infarction patients in relation to pain-to-PCI elapsed time
- Article 7. Microparticles from thrombin-induced platelets have a complex proteomic profile rich in prothrombotic components
- Article 8. Exosomal microRNA signature predicts future ischemic events in hypercholesterolemic patients